PLoS ONE (Jan 2020)

In vivo elongation of thin filaments results in heart failure.

  • Lei Mi-Mi,
  • Gerrie P Farman,
  • Rachel M Mayfield,
  • Joshua Strom,
  • Miensheng Chu,
  • Christopher T Pappas,
  • Carol C Gregorio

DOI
https://doi.org/10.1371/journal.pone.0226138
Journal volume & issue
Vol. 15, no. 1
p. e0226138

Abstract

Read online

A novel cardiac-specific transgenic mouse model was generated to identify the physiological consequences of elongated thin filaments during post-natal development in the heart. Remarkably, increasing the expression levels in vivo of just one sarcomeric protein, Lmod2, results in ~10% longer thin filaments (up to 26% longer in some individual sarcomeres) that produce up to 50% less contractile force. Increasing the levels of Lmod2 in vivo (Lmod2-TG) also allows us to probe the contribution of Lmod2 in the progression of cardiac myopathy because Lmod2-TG mice present with a unique cardiomyopathy involving enlarged atrial and ventricular lumens, increased heart mass, disorganized myofibrils and eventually, heart failure. Turning off of Lmod2 transgene expression at postnatal day 3 successfully prevents thin filament elongation, as well as gross morphological and functional disease progression. We show here that Lmod2 has an essential role in regulating cardiac contractile force and function.